Iovance Biotherapeutics, Inc.(NASDAQ : IOVA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|VRTX||Vertex Pharmaceuticals, Inc.||1.64%||292.74||1.9%||$426.74m|
|GILD||Gilead Sciences, Inc.||0.66%||61.49||1.0%||$374.72m|
|REGN||Regeneron Pharmaceuticals, Inc.||2.30%||627.69||2.6%||$352.35m|
|SNSS||Sunesis Pharmaceuticals, Inc.||0.00%||3.87||0.7%||$270.53m|
|GOVX||GeoVax Labs, Inc.||-10.16%||2.89||0.0%||$143.97m|
|CRSP||CRISPR Therapeutics AG||0.08%||81.47||0.6%||$132.88m|
|RYTM||Rhythm Pharmaceuticals, Inc.||5.02%||21.26||0.0%||$95.89m|
|PLRX||Pliant Therapeutics, Inc.||-0.11%||18.89||0.0%||$95.31m|
|BMRN||BioMarin Pharmaceutical, Inc.||-0.63%||95.22||4.2%||$94.74m|
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.